Functional specificity of Akt isoforms in cancer progression

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• Akt/Protein Kinase B (PKB) kinases are critical regulators of cellular homeostasis.
• Hyperactivation of Akt signaling pathways is a significant factor in human cancer progression, influencing tumor growth, chemoresistance, and metastasis.
• Understanding the distinct roles of the three Akt isoforms (Akt1, Akt2, Akt3) is essential for deciphering their specific contributions to cancer development.

Purpose of the Study:

• To elucidate the differential roles of Akt1, Akt2, and Akt3 isoforms in various human cancers.
• To explore the mechanisms by which Akt isoforms exert distinct or opposing effects in cancer cells.
• To highlight the necessity of isoform-specific targeting for effective anticancer drug development.

Main Methods:

• Review and synthesis of existing literature on Akt isoform function in cancer.
• Analysis of Akt isoform expression patterns and alterations in different cancer types.
• Examination of proposed mechanisms for differential Akt isoform activity, including tissue-specific expression, substrate specificity, and localization.

Main Results:

• Akt1 is predominantly implicated in tumor growth, invasion, and chemoresistance across various carcinomas.
• Akt2 is primarily associated with cancer cell invasion, metastasis, and survival, with alterations frequently observed in breast, ovarian, pancreatic, and colorectal cancers.
• Akt3's role is more restricted, mainly contributing to tumor growth and drug resistance in melanomas, gliomas, and some breast cancers.

Conclusions:

• The specific Akt isoform involved dictates its role in cancer progression, necessitating consideration of individual isoform functions.
• Mechanisms such as tissue-specific expression, distinct substrate interactions, and cytoskeletal localization contribute to the differential roles of Akt isoforms.
• Developing effective Akt inhibitor drugs requires targeting the specific isoform driving a particular tumor's progression.